Respiratory Medicine at RPH provides a comprehensive tertiary service in respiratory diseases, including acute in-patient care, a consult service and outpatient care across all respiratory sub-specialty areas. The Department is supported by Specialist Respiratory Nurses and a full range of pulmonary physiology testing. 

Research interests and focus

Royal Perth Hospital Respiratory Research supports a range of commercial, international, multi-centre, grant funded (Investigator initiated), and local academic students in their research projects through conducting clinical trials focusing on the efficacy and safety of various pharmaceutical therapies in patients with Pulmonary Nontuberculous Mycobacterial Infection.  The focus areas for research are patients with Nontuberculous mycobacteria (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) and Mycobacterium abscessus (MABS). 

In addition to the above work, the Respiratory Department is a registered site contributing to the Australasian Interstitial Lung Disease Registry and maintains research links with other local tertiary centres to contribute to multicentre studies in Pleural disease and Lung Cancer.

Example projects 

MACOS Mycobacterium avium Complex Observational Study – Cohort Observational Study of Second-line Treatment for MAC Lung Disease Aiming to Determine the Optimal Treatment 
CPI:  Dr. Justin Waring

MaCRO2 AN2 Therapeutics EBO-301:  A Phase 2/3, Randomised, Double-blind, Placebo-controlled, Multi-centre, Prospective Study to assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patient s with Treatment-refractory Mycobacterium avium Complex Lung Disease (EBO–301–external site)
CPI:  Dr Justin Waring

ENCORE INS-416 a Randomised, Double-Blind, Placebo-Controlled, Active Comparator, Multi-centre Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed NTM Lung Infection Caused by MAC (ENCORE – external site)
CPI:  Dr. Ruad Perera

FORMaT:  A multi-centre, randomised, multi-arm, adaptive platform trial in people with or without cystic fibrosis Finding the Optimal Regimen for Mycobacterium abscessus Treatment (FORMaT – external site)
CPI:  Dr. Tim Whitmore

ICoN-1 MKC-CI-002:  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study the Efficacy and Safety of Treatment with MKND-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by and Open-Label Extension (ICoN-1 – external site)
CPI:  Dr. Justin Waring